These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 30913932)

  • 1. Clinical management of difficult to treat macroprolactinomas.
    Sahakian N; Castinetti F; Dufour H; Graillon T; Romanet P; Barlier A; Brue T; Cuny T
    Expert Rev Endocrinol Metab; 2019 May; 14(3):179-192. PubMed ID: 30913932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Dopamine-agonist resistant prolactinomas: diagnosis and management].
    Musolino NR; Passos VQ
    Arq Bras Endocrinol Metabol; 2005 Oct; 49(5):641-50. PubMed ID: 16444347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current approach to treatments for prolactinomas.
    Tirosh A; Shimon I
    Minerva Endocrinol; 2016 Sep; 41(3):316-23. PubMed ID: 26399371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Prolactinoma.
    Inder WJ; Jang C
    Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists.
    Passos VQ; Fortes MA; Giannella-Neto D; Bronstein MD
    Neuroendocrinology; 2009; 89(2):163-70. PubMed ID: 18791324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolactinomas Resistant to Dopamine Agonists: Pathophysiology and Treatment.
    Shimon I
    Arch Med Res; 2023 Dec; 54(8):102883. PubMed ID: 37689507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug resistance mechanisms in dopamine agonist-resistant prolactin pituitary neuroendocrine tumors and exploration for new drugs.
    Cheng J; Xie W; Chen Y; Sun Y; Gong L; Wang H; Li C; Zhang Y
    Drug Resist Updat; 2024 Mar; 73():101056. PubMed ID: 38277755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolactinomas in pregnancy: considerations before conception and during pregnancy.
    Glezer A; Bronstein MD
    Pituitary; 2020 Feb; 23(1):65-69. PubMed ID: 31792668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of resistant prolactinomas.
    Olafsdottir A; Schlechte J
    Nat Clin Pract Endocrinol Metab; 2006 Oct; 2(10):552-61. PubMed ID: 17024154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine agonist-resistant prolactinomas.
    Oh MC; Aghi MK
    J Neurosurg; 2011 May; 114(5):1369-79. PubMed ID: 21214334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on prolactinomas. Part 2: Treatment and management strategies.
    Wong A; Eloy JA; Couldwell WT; Liu JK
    J Clin Neurosci; 2015 Oct; 22(10):1568-74. PubMed ID: 26243714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists.
    Neff LM; Weil M; Cole A; Hedges TR; Shucart W; Lawrence D; Zhu JJ; Tischler AS; Lechan RM
    Pituitary; 2007; 10(1):81-6. PubMed ID: 17285366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of TGF-β/Smad signaling in dopamine agonist-resistant prolactinomas.
    Li Z; Liu Q; Li C; Zong X; Bai J; Wu Y; Lan X; Yu G; Zhang Y
    Mol Cell Endocrinol; 2015 Feb; 402():64-71. PubMed ID: 25578603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistant prolactinomas.
    Vasilev V; Daly AF; Vroonen L; Zacharieva S; Beckers A
    J Endocrinol Invest; 2011 Apr; 34(4):312-6. PubMed ID: 21406957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperprolactinemia and prolactinoma.
    Romijn JA
    Handb Clin Neurol; 2014; 124():185-95. PubMed ID: 25248588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms.
    Pivonello C; Patalano R; Negri M; Pirchio R; Colao A; Pivonello R; Auriemma RS
    Front Endocrinol (Lausanne); 2021; 12():791633. PubMed ID: 35095761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of pituitary tumor apoplexy during treatment of prolactinomas with dopamine agonists: a systematic review.
    Carija R; Vucina D
    CNS Neurol Disord Drug Targets; 2012 Dec; 11(8):1012-4. PubMed ID: 23244423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotype and resistance patterns of 10 resistant prolactinomas.
    Araujo-Castro M; Abad López A; Aller Pardo J; Kanaan Kanaan L; Palacios García N
    Endocrinol Diabetes Nutr (Engl Ed); 2020 Mar; 67(3):194-204. PubMed ID: 31201099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolactinomas in males: any differences?
    Duskin-Bitan H; Shimon I
    Pituitary; 2020 Feb; 23(1):52-57. PubMed ID: 31802331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The long noncoding RNA-H19/miRNA-93a/ATG7 axis regulates the sensitivity of pituitary adenomas to dopamine agonists.
    Wu Z; Zheng Y; Xie W; Li Q; Zhang Y; Ren B; Cai L; Cheng Y; Tang H; Su Z; Wu ZB
    Mol Cell Endocrinol; 2020 Dec; 518():111033. PubMed ID: 32946927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.